UNITED STATES DEPARTMENT OF LABOR

+ + + + +

ADVISORY BOARD ON TOXIC SUBSTANCES AND WORKER HEALTH

+ + + + +

WORKING GROUP ON PRESUMPTIONS

+ + + + +

MEETING

+ + + + +

WEDNESDAY, JUNE 21, 2017

+ + + + +

The Advisory Board met telephonically at 1:00 p.m. Eastern Time, Steven Markowitz, Chair, presiding.

MEMBERS

SCIENTIFIC COMMUNITY:

KENNETH Z. SILVER LESLIE I. BODEN

MEDICAL COMMUNITY:

STEVEN MARKOWITZ, Chair VICTORIA A. CASSANO

CLAIMANT COMMUNITY:

KIRK D. DOMINA GARRY M. WHITLEY FAYE VLIEGER

NEAL R. GROSS

BOARD MEMBERS ALSO PRESENT:

KIRK DOMINA

DESIGNATED FEDERAL OFFICIAL:

CARRIE RHOADS

1	P-R-O-C-E-E-D-I-N-G-S
2	1:05 p.m.
3	MS. RHOADS: Hi everybody. My name's
4	Carrie Rhoads. I'd like to welcome you to today's
5	teleconference meeting of the Department of Labor's
6	Advisory Board on Toxic Substances and Worker
7	Health, the Presumptions Working Group.
8	I am the board's designated federal
9	officer or DFO for today's meeting.
10	First of all we appreciate the time and
11	the work of our board members in preparing for this
12	meeting and for their time spent working after.
13	I'll introduce board members and take
14	a quick roll call. Dr. Steven Markowitz is the
15	chair of this group and chair of the advisory board.
16	CHAIR MARKOWITZ: Here.
17	MS. RHOADS: And the members are Dr.
18	Victoria Cassano.
19	MEMBER CASSANO: Here.
20	MS. RHOADS: Ms. Faye Vlieger.
21	MEMBER VLIEGER: Present.
22	MS. RHOADS: Dr. Leslie Boden. Dr.

1	Boden, are you on the line?
2	MEMBER BODEN: Here.
3	MS. RHOADS: Thanks. Mr. Garry
4	Whitley.
5	MEMBER WHITLEY: Here.
6	MS. RHOADS: Dr. Ken Silver.
7	MEMBER SILVER: Here.
8	MS. RHOADS: Dr. John Dement and Dr.
9	Laura Welch are both in this group but could not
10	make the call today. And Mr. Kirk Domina is also
11	on the line with us.
12	In the room with me is Melissa Schroeder
13	from SIDEM, our contractor.
14	Today's meeting is scheduled from 1
15	o'clock to 3:30 Eastern time. I don't know if we'll
16	take a break. If the discussion allows and Dr.
17	Markowitz wants to that is fine.
18	Copies of all meeting materials and any
19	written public comments are or will be available
20	on the board's website under the heading Meetings
21	and a listing there for this meeting.
22	The documents will also be up on the

1	WebEx screen so everyone can follow along with the
2	discussion.
3	The board's website can be found at
4	dol.gov/OWCP/energy/regs/compliance/advisoryboar
5	d.htm.
6	When you visit the website after
7	clicking on today's meeting you'll see a page
8	dedicated entirely to the meeting.
9	The webpage contains publicly
10	available material submitted to us in advance and
11	we'll publish any materials that are provided to
12	this subcommittee.
13	There you should also find today's
14	PowerPoint presentation as well as instructions
15	for participating remotely.
16	If you are participating remotely and
17	you're having a problem please email us at
18	energyadvisoryboard@dol.gov.
19	If you're joining by WebEx please note
20	that the session is for viewing only and will not
21	be interactive.
22	The phones will also be muted for

non-advisory board members.

If you're a speaker and you're not speaking please mute your phone because we're getting a lot of background noise right now.

Please note that we do not have a scheduled public comment session today. The call-in information has been posted on the website so the public can listen in but not participate in the discussion.

The advisory board voted at its April 2016 meeting that the subcommittee meeting should be open to the public. A transcript and minutes will be prepared from today's meeting.

During board discussions today as we're on a teleconference line please speak clearly enough for the transcriber to understand. When you begin speaking especially at the start of the meeting please state your name so we can get an accurate record of the discussion.

And I'd like to ask our transcriber to let us know if you're having any issues with hearing or with recording.

As the DFO I see that the minutes are 1 prepared and ensure they're certified by the chair. 2 The minutes of today's meeting will be available 3 on the website no later than 90 calendar days from 4 5 today. Τf they're available we'll 6 sooner 7 publish them sooner as well. We'll also be publishing verbatim 8 transcripts which are obviously more detailed in 9 10 nature. Those transcripts should be available on 11 the website within 30 days. 12 I'd also like to remind the advisory 13 board members that there are some materials that have been provided to you in your capacity as 14 special government employees and members of the 15 16 board which are not for public disclosure and can't be shared or discussed publicly including in this 17 18 meeting. 19 Please be aware of this as we continue with the meeting today. These materials can be 20 21 discussed in a general way which does not include

using any personally identifiable information such

1	as names, addresses, specific facilities of the
2	cases being discussed.
3	And with that I convene the meeting of
4	the Advisory Board on Toxic Substances and Worker
5	Health, Presumptions Working Group. And I'm going
6	to turn it over to Dr. Markowitz.
7	CHAIR MARKOWITZ: Thank you, Carrie.
8	And actually, thank you Carrie for all the support
9	work and work you do with the board. It's extremely
10	useful.
11	I'd like to welcome people onto this
12	call from the Presumptions Working Group. I'd also
13	like to welcome any members of the public who are
14	listening in.
15	We don't have a public comment period
16	during this working group meeting or for that matter
17	any of the subcommittee calls as Carrie mentioned.
18	However, we do welcome always written
19	public comments which we read and try to take into
20	consideration in terms of our discussions and
21	decisions.
22	I think first we should probably just

1	go around in case there are any members of the public
2	who aren't familiar with board members and just
3	very briefly identify ourselves.
4	I'm Steven Markowitz. I'm an
5	occupational medicine physician and
6	epidemiologist, and professor at the City
7	University of New York.
8	And Carrie, if you could just cite
9	peoples' names and then they can respond. That's
10	probably the easiest way.
11	MS. RHOADS: Okay. Dr. Cassano.
12	MEMBER CASSANO: This is Dr. Victoria
13	Cassano. I am also an occupational and
14	environmental medicine physician. Retired Navy
15	physician and also worked at VA in the central
16	office doing environmental health policy. And now
17	have my own company. Thank you.
18	MS. RHOADS: Okay. Ms. Vlieger.
19	MEMBER VLIEGER: Faye Vlieger, former
20	Hanford worker and worker advocate.
21	MS. RHOADS: Dr. Boden?
22	MEMBER BODEN: This is Les Boden. I'm

1	a professor at Boston University School of Public
2	Health.
3	MS. RHOADS: Mr. Whitley?
4	MEMBER WHITLEY: Garry Whitley. I
5	worked at Y-12 National Security Complex Oak Ridge
6	for 42 years and worked with the worker health
7	protection program.
8	MS. RHOADS: Dr. Silver?
9	MEMBER SILVER: Ken Silver, associate
10	professor of environmental health at East Tennessee
11	State University.
12	MS. RHOADS: Mr. Domina.
13	MEMBER DOMINA: Kirk Domina. I'm the
14	employee health advocate for the Hanford Atomic
15	Metal Trades Council. We're from Washington.
16	I've been here 34 years and we represent
17	approximately 2,600 current workers.
18	MS. RHOADS: Okay. Go ahead, Dr.
19	Markowitz.
20	CHAIR MARKOWITZ: Thank you. So the
21	agenda for today really is to discuss the PowerPoint
22	which I prepared which really principally addresses

one issue which are looking at the medical criteria 1 for the diagnosis or the use of medical information 2 3 for application to claims under EEOICPA with relation to various asbestos related diseases. 4 And then at the end I open up the --5 try and open up the discussion to consideration 6 7 of other issues for the future in terms presumptions. 8 Is there any other agenda item that 9 10 members of the board would like to propose or discuss today? 11 Okay, well if something comes up I think 12 13 we're going to have time because I don't think the agenda so far will occupy nearly all of our time, 14 although I always seem to underestimate how much 15 discussion is generated. But regardless. 16 And by way of taking a break we'll see 17 how things go. In an hour or an hour and 15 minutes 18 19 if it looks like we're going to go for quite a while longer then I'll call for a break. 20 21 On the presumptions we've been dealing 22 with scientific technical medical issues that some

1	members of the board are much more familiar with
2	than other members.
3	And I just want to reiterate that if
4	there are issues, terms, or comments that people
5	don't understand we can very quickly explain things
6	in a way that allows everybody to understand.
7	Because everybody makes important
8	contributions and I really don't want folks feeling
9	shut out in any sense because the doctors are
10	talking about medical stuff.
11	So we should be able to communicate in
12	a way where everyone understands and can
13	contribute. So I probably should have said that
14	before, but in any event I feel that reflects the
15	spirit of the board.
16	So let's go to the PowerPoint. And go
17	to the first slide.
18	Now, just to summarize, this is the work
19	we've already done on presumptions. And you see
20	listed the first four content, either diseases or
21	exposures.
22	We've mostly focused on exposure

presumptions rather than on helping DOL make a determination about how to recognize a diagnosis of disease.

We did that for asthma but we didn't really do that for COPD, for asbestos-related diseases, and we didn't weigh in on how they should look at hearing loss in terms of diagnosing hearing loss.

We did, however, weigh in the on exposure side. And then early had on we actually cessation of use of recommended а presumption for post-95 toxic exposures, presumption which is the recommendation that DOL has accepted.

And then we earlier this week formally endorsed as a board the current presumption, so that's not a recommended change at all in how DOL treats sarcoidosis and its equivalents with CBD if a person is a covered beryllium employee. So that's the work we've done so far.

And we've concentrated on I think fairly common outcomes for which people make

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

claims, especially on the respiratory disease side, 1 but also on the hearing loss. So the next slide. 2 3 So, I think it was in the last meeting when we were discussing asbestos-related diseases 4 that someone suggested that maybe we should look 5 at the medical side, at the diagnostic side, and 6 7 see if there's some helpful suggestions that we could make to DOL in terms of how they recognize 8 various asbestos-related disease. 9 10 Now, from their manual -- by the way, if you haven't seen the updated procedures manual, 11 updated, the date was April 2017, you should take 12 13 a look. It's very nicely organized. I don't think the content has been 14 changed, but it's organized in a way that makes 15 16 it much easier to locate things. So as we actually discussed in April 17 that the current program recognizes a variety of 18 asbestos-related diseases including those not --19 that don't represent cancer, and that's asbestosis 20 21 or scarring of the lung tissue itself due to

Pleural plagues and pleural thickening,

asbestos.

scarring of the covering of the lungs, the pleura. 1 actually mentioned 2 They something 3 which is fairly uncommon and we haven't discussed before, but sometimes asbestos after many years 4 fluid to accumulate, fluid that's 5 causes elaborated by this covering of the lung, the pleura. 6 7 And it's called pleural effusion. Accumulates at the bottom of the lung and then eventually 8 resolves. 9 10 It's not a malignancy. It usually leaves behind some scarring, but it's something 11 12 actually that the program and the procedure manual 13 recognizes. So even though we didn't suggest it in April it is part of the disease spectrum of the 14 15 program. 16 And then secondly, the various malignancies that are recognized by the program 17 which are malignant mesothelioma, cancer of the 18 pleura. 19 Now, by the way, mesothelioma occurs 20 elsewhere in the body besides in the chest. 21 Ιt

occurs about 10 percent of the time in the abdomen

where it's called peritoneal mesothelioma. 1 And then less than 1 percent of the time 2 at other locations. 3 4 And we're not going to discuss mesothelioma outside of the chest today because 5 the procedure manual doesn't -- I don't think it 6 addresses mesothelioma of the abdomen or otherwise 7 known as peritoneal mesothelioma. 8 And so we're just sort of skipping over 9 10 that for now. It's extremely rare and there are about 250 cases total in a year among Americans, 11 12 350 million people of which there are a total of 13 250 cases total per year of peritoneal mesothelioma. 14 So we're not going to address that 15 16 today. And then the other cancers including 17 lung cancer, and cancer of the ovary, and cancer 18 19 of the larynx. Next slide. By the way, I'll occasionally take a 20 21 breath so jump in with comments, questions, or 22 interrupt me so that this isn't a monologue.

At certain points I'll open it up for 1 specific comments. 2 Now on the next few slides what I do, 3 I simply abstracted the current language from the 4 procedure manual on how claims examiners and the 5 program as a whole view medical evidence of 6 asbestosis and other conditions. 7 So where at the top of the slide it says 8 the EEOICPA Procedure Manual Chapter 18 this is 9 10 the language that they use. So the claims examiner is instructed 11 12 for a claim of asbestosis to look at a number of different sources of evidence. 13 And they look for an opinion of 14 qualified physician. This is presumably the 15 16 treating physician, at least initially. And that that opinion is based on a chest X-ray finding, 17 a CAT scan finding, CT scan finding, an MRI which 18 19 is a fancier imaging study of the chest, pulmonary function tests or breathing tests, or lung biopsy. 20 Or, and/or another source of evidence 21

is the physician report from the DOE's former worker

program.

And/or another source of evidence is the death certificate.

So, I have to say, and here I'm going to open it up for comments, I have to say I'm a little puzzled still about how this works.

The claims examiner is collecting information the claimant has sent in. They get hopefully some report from the treating physician and the treating physician say in a case of asbestosis might say this is asbestosis that the person has and they may or may not cite the evidence for that diagnosis.

And presumably the claims examiner gets a report of the chest X-ray, or the CT scan, or the biopsy.

And what I'm trying to understand is does the claims examiner look at not just the physician report, but they're looking at the chest X-ray report and the CT report, the lung biopsy report, and they're trying to see whether what they are reading in those reports constitutes

asbestosis, or there are findings that allow them 1 with some confidence to say yes, this person's claim 2 is for asbestosis. 3 Is that your -- speaking to the other 4 board members here -- your general impression of 5 the process of how the claims examiner works? 6 7 MEMBER CASSANO: Steve, I was kind of confused as you know from my email about the --8 I'm not quite sure whether it's all -- I quess that 9 10 they're saying that these are all the sources of evidence, but I don't think any of them are used 11 12 definitively. 13 I think there's a lot of -- what's the looking for. lot 14 word I'm There's of interpretation allowed here. 15 16 So this is what I wrote you about, DOE WP physician findings. And that's when I asked, 17 gee, does it mean that only -- that any other 18 qualified MD, there has to also be chest X-rays, 19 CT, MRI, before DOE from a worker program physician 20 21 all you need is that physician's statement that

it's asbestosis.

1	So I don't know whether you need any
2	combination of these, or any one of these. To me
3	it's confusing and I presume then that it's probably
4	confusing for CEs as well. I don't know.
5	CHAIR MARKOWITZ: Right. Other
6	comments?
7	MEMBER VLIEGER: This is Faye. What
8	I find with asbestos diagnosis, unless it's one
9	of the former worker physicians who's actually
10	looking at it and saying that this is asbestosis
11	it's very hard to get a diagnosis from your
12	pulmonary physician because they feel unable to
13	make a diagnosis from what they see.
14	And so I'm not sure how to change that.
15	Maybe include the wording of what they're supposed
16	to be looking for more clearly.
17	But even at that if you show them the
18	document they say well, I don't know how to diagnose
19	asbestos. And this is from qualified
20	pulmonologists.
21	So I don't know if we can fix that or
22	not.

My experience is that you have some 1 piece of evidence, not all of them, and then you 2 have to have a physician stating that this is what 3 this is. 4 In the past the former worker program 5 physicians were not accepted because it wasn't the 6 7 attending physician. That's considered a one-time occupational medicine physician which I 8 appalling, but that's what they've been doing. 9 10 CHAIR MARKOWITZ: And later I'm going to show some slides of the former worker program's 11 12 language that they -- or basis for their decisions. 13 Other comments. MEMBER WHITLEY: This is Garry. 14 In Oak Ridge our pulmonary doctors gives a diagnosis 15 16 and writes the letter, sends it -- gives the claimant a letter and they send a letter that 17 they've been diagnosed with asbestosis. 18 And usually they don't question it 19 20 pretty much. And the doctors here in Oak Ridge, 21 if you've been working with asbestos in groups that

have, and they diagnose it, that's pretty much what

1 all has to happen. I had a friend this week that just told 2 me he got his claim of asbestosis and it hadn't 3 been probably three or four months since he filed. 4 MEMBER CASSANO: And that was because 5 the physician in the local area -- is that just 6 7 a local physician or is that within a former worker program? 8 9 MEMBER WHITLEY: No, it's a local 10 pulmonologist in this area. We've got several right here in Oak Ridge and they see a lot of people. 11 12 They diagnose asbestos pretty often. 13 MEMBER CASSANO: I think people that are used to seeing individuals exposed to asbestos 14 don't have difficulty diagnosing it. 15 16 you're occupational physician, an 17 pulmonologist, or an internist. But even pulmonologists who don't see 18 it are uncomfortable diagnosing it I think. 19 They call it either pulmonary fibrosis or they --20 whatever they're going to call the small -- I'm 21

not thinking straight for some reason, but whatever

1	they're going to call what they see on a chest X-ray
2	they're uncomfortable calling it asbestosis.
3	A lot of times because they don't ever
4	ask for an occupational history so they don't know
5	the person's been exposed to asbestos.
6	CHAIR MARKOWITZ: For the transcriber
7	that interchange was between Garry Whitley and Dr.
8	Tori Cassano.
9	MEMBER CASSANO: Sorry about that.
10	CHAIR MARKOWITZ: That's okay. Garry
11	Whitley is the one with the attractive accent so
12	you can always recognize him.
13	MEMBER CASSANO: Yes, I'm the one that
14	speaks like a doctor.
15	CHAIR MARKOWITZ: Other comments?
16	MEMBER SILVER: This is Ken. This is
17	pretty interesting. We have two extremes laid out.
18	One is at Oak Ridge where the pulmonologists are
19	experienced and cooperative in making the
20	diagnosis.
21	And then we have Faye's experience
22	where they're not. And it seems an important

question for us is how much discretion do the claims 1 examiners have between those two poles and how do 2 3 they exercise it. And they qualified in the case of Oak 4 Ridge to overrule or are they qualified to construct 5 a diagnosis for a Hanford worker who didn't get 6 7 one from their pulmonologist. MEMBER BODEN: This is Les Boden. I'm 8 wondering following up on this conversation whether 9 10 there ought to be some either information or guidance for the pulmonologists who are treating 11 12 people. So information might be providing them 13 with information about whether that person worked 14 on a job that DOE would consider to be potentially 15 16 asbestos exposed, or guidance about how to think about what DOE is looking for from them which would 17 18 presumably include some information about exposure 19 to asbestos. This is for Faye's physicians and not 20 21 for Garry's I guess. 22 MEMBER CASSANO: What I find with treating physicians a lot that are experienced at either primary care or the (inaudible) doc is that even if you give them all of that they're always going to waffle. I see this all the time.

They're never going to say it's at least -- it's most probably. That's the best you're going to get. You're never going to get even an at least as likely as not statement, or a definitive statement that what they're seeing on chest X-ray on the person's pulmonary function is due to asbestos.

They're going to say is consistent with asbestos, consistent with asbestos exposure, probably due to asbestos, or possibly due to asbestos.

I find that most of them aren't going to pin etiologic certainty with something that does not -- even with stuff that they are very familiar with. A lot of times they won't do it.

So I think we need to find some way of giving the CEs enough information. If they have a definitive diagnosis then that's fine, but if

1	they've got a chest X-ray that has fibrosis or has
2	B reading that shows one zero B read or something
3	like that.
4	I think it needs to go to a CMC.
5	Because I don't think for the most part without
6	something clear that says asbestosis that it goes
7	to radiology reports or MRI, CT, or whatever that
8	says definitively asbestosis.
9	They need that clinical
10	interpretation.
11	CHAIR MARKOWITZ: This is Steve. And
12	that's probably the way it works.
13	In fact, after this call I'll ask for
14	some clarification from DOL about how this works
15	in practice.
16	But we're going to get into some
17	specific language on medical evidence which I think
18	will help the process. Even if the process doesn't
19	change it'll help the CE by giving more specifics
20	about diagnosis.
21	It'll help the treating physician
22	because they'll be able to look at the specifics

that by the way exist in some other aspects of the program, some of the statutory, for instance, beryllium and silica, actually in the act.

It's not in the act about asbestosis nor in the procedure manual.

So let's continue with the next slide. So this is cited from the procedures manual about the opinion of the qualified physician who states on any or all of the following, pulmonary interstitial fibrosis with or without heart enlargement, CT or MRI finding of lung scarring, pleural thickening, heart enlargement, pulmonary function test finding of restriction. That's lower lung volumes. The person can't breathe sufficiently.

And the PFT requires a physician interpretation or lung biopsy. And it mentions that lung biopsy sputum cytology which is simply looking at cells in sputum or a bronchial lavage which is putting fluid into the lung and then taking it out and looking at cells. It often shows asbestos bodies which are old asbestos fibers that

are coated with protein and have a very distinct 1 2 appearance. 3 Those findings are helpful but not So that's kind of a summary from the 4 definitive. manual as to how the CE and others look at the 5 information that the treating physician provides. 6 7 Next. And/or the former worker program. And 8 the assessment. And the language of the procedure 9 10 manual says they accept the physician assessment of asbestosis or asbestos related lung disease. 11 12 And from the language frankly looks 13 like the CE doesn't necessarily have to look at the data that we just went over in the previous 14 slide, meaning chest X-ray, CT results or the like. 15 16 It looks like it can be based on the 17 FWP determination. And part of the logic of that would be frankly the FWP determination is based 18 on the chest X-ray and occupational history which 19 20 we'll go over in a second. And then the third source of evidence 21 22 -- next slide -- that the CE or the claimant process

can examine is the death certificate.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

And here they want to see asbestosis on the death certificate as either the cause or a contributing factor.

And if the death certificate says something other than asbestosis because it very easily could say pulmonary fibrosis, or fibrosis of the lung, or interstitial fibrosis, or something that is kind of equivalent but less specific than asbestosis then the claims examination process needs evidence, other evidence to support the diagnosis of asbestosis which makes a lot of sense. Next slide.

moving The And onto cancers. procedure manual requires that the CEfind confirmation of the diagnosis of mesothelioma of the pleura. And it's not specified exactly what that is although in practice it's almost assuredly it's going to be the pathology report, examination of the tissue of the cancer.

Again, from the procedure manual, now moving onto pleural plaques and pleural effusions

this is in the non-malignant category, plaques being the scarring of the pleura.

And then the supportive medical evidence that is examined in the claims process includes the physician diagnosis, some chest X-ray or CT, in other words some imaging evidence of pleural plaques or pleural thickening which is not due to surgery or trauma.

And we've got rounded atelectasis which is quite specific to asbestos. What happens is that the pleura sits on top of the lung and when it gets scarred, and the scarring can get exuberant or kind of aggressive, it can envelop a section of the nearby lung and kind of wrap -- the scarring of the pleura wraps around that section, a small section of the lung.

And it's called rounded atelectasis.

And it has the potential to appear in the chest

X-ray or CT scan as fairly specific for

non-malignant asbestos related disease.

And then finally the presence of bilateral pleural effusions.

So again, these are just the pieces that 1 are examined in the process of looking at a claim 2 for pleural plaques or pleural effusions. 3 4 By the way these are two separate This pleural plague, the thickening, 5 entities. the scarring is one thing, and the pleural effusion 6 7 is something separate, much less common. MEMBER BODEN: This is Les Boden. Can 8 I interrupt just for a second to clarify for me? 9 10 see these various pieces supportive medical evidence. 11 Is there any guidance to the CE about how to use these various 12 13 pieces to come to a conclusion? And that would hold clearly for the asbestos. 14 CHAIR MARKOWITZ: Yes. So if you go 15 16 to the previous slide just so we can look at what we were looking at. 17 I don't know what exists outside the 18 procedure manual because I didn't really look at 19 the circulars, go around the circular bulletins 20 or any other sources of guidance. So there may 21

be something else somewhere else, but probably not

1	much actually.
2	This is a summary of how the CE looks
3	at these cases for claims of information.
4	MEMBER BODEN: Right.
5	CHAIR MARKOWITZ: There's no more
6	specificity than this. Unless I somehow didn't
7	summarize these properly, but I think I got the
8	keywords right.
9	MEMBER BODEN: Okay. So I'm thinking,
10	I'm looking at this is like how many of the four
11	things on this list would I need before I was
12	convinced that I should approve the claim for
13	pleural plaques.
14	Or which ones are particularly
15	convincing to me. That's not part of this,
16	correct?
17	CHAIR MARKOWITZ: Not that I saw. I
18	mean, what probably happens, my guess is that
19	physician diagnosis, the physician cites an imaging
20	study or the CT scan as evidence.
21	That would be predominantly in
22	asbestos disease that would be the typical or the

1	expected kind of scenario.
2	MEMBER BODEN: Right.
3	CHAIR MARKOWITZ: Now, if the CE just
4	sees a physician diagnosis without reference to
5	a chest X-ray I'm not sure what happens.
6	MEMBER BODEN: I would suspect not be
7	convincing.
8	CHAIR MARKOWITZ: Right. Nor frankly
9	should it.
10	MEMBER BODEN: Yes, appropriately so.
11	CHAIR MARKOWITZ: Right, right. So,
12	next slide.
13	And then there is instruction on these
14	specific plaques and effusions that the claims
15	examiner will consult either with the treating
16	physician or the CMC if evidence was inconclusive.
17	If the pleural thickening is in an area
18	of surgery or trauma, or if there's other
19	evidence of other causes of a pleural effusion is
20	present.
21	I would just tell you pleural
22	thickening, if a person has a traumatic rib

fracture, or if the person undergoes chest surgery it would typically leave behind an area of pleural thickening in which case you wouldn't really ascribe that pleural thickening or plaque to asbestos. You would say it's due to that trauma or surgery. It's not necessarily -- all the time.

And then pleural effusions, this is item number three, pleural effusions are very common. Asbestos related, benign pleural effusion is very uncommon and so it makes a lot of sense to look for other more ready explanations for pleural effusions. Next slide.

So, just to move to what the former worker program does. These are surveillance case definitions so these are not diagnostic. These are how we identify for the purposes of reporting to DOE in large populations that we screen how we identify a case of asbestosis which is they have a history of exposure to asbestos or a job title in which it's reasonably likely to have exposure to asbestos.

And we require a B reading which is a

chest X-ray by a physician who is specially trained 1 and passed a test given by NIOSH for reading X-rays 2 for dust diseases. 3 The B reading of a standard chest film 4 demonstrating bilateral irregular opacities in the 5 lung tissue itself with a specific shape and size. 6 7 And stu means irregular. And the profusion score meaning a 8 density of the lowest level or higher, the lowest 9 10 level being 150 which is a relatively slight disease. 11 12 So there's some specificity. It can't 13 exactly be transferred over to the program, but it's an example of how the former worker program 14 looks at it. 15 16 And notice that if she's not on the film film, it doesn't discuss pulmonary 17 chest function tests or any other source of evidence. 18 19 Next slide. Sorry, this is Les 20 MEMBER BODEN: 21 So it appears to me, and I don't really again. know this stuff that well, that this would be 22

1	somewhat more restrictive than you might get from
2	using the other pieces of evidence that were talked
3	about before, more consistent maybe, but maybe also
4	more restrictive or not.
5	CHAIR MARKOWITZ: Well, it doesn't
6	address the death certificate obviously. The FWP
7	or screening program.
8	MEMBER BODEN: But putting the death
9	certificate aside. So the question is at least
10	in your opinion would it be would using this
11	definition only screen in fewer cases than.
12	CHAIR MARKOWITZ: So it depends on
13	probably not many. It could be more restrictive.
14	It depends on how the current guidelines are
15	applied.
16	For instance, notice that in this
17	definition that it's nothing about breathing tests.
18	MEMBER BODEN: Right.
19	CHAIR MARKOWITZ: If the claims
20	examiner is looking at a case in which a person
21	reports asbestos exposure so that's off the table
22	has a normal X-ray, or X-ray findings that are

1	a lot less specific than what we were looking at
2	on the screening here, but has restriction on
3	pulmonary function.
4	Would the claims examiner, the treating
5	physician, the claims examiner or the CMC consider
6	that to be sufficient to say it's asbestosis.
7	In practice they might. Would they be
8	right? Unlikely. But they could do that.
9	MEMBER BODEN: The other problem with
10	this for general use would be that you'd need to
11	have a B reader.
12	CHAIR MARKOWITZ: Oh yes, yes. This
13	is too restrictive in that sense because most people
14	aren't going to people who are B readers. Most
15	B readers are radiologists. They're not primary
16	care doctors, or pulmonary specialists.
17	And if you send their X-ray over to
18	Methodist Hospital in Oak Ridge, or Baptist over
19	in Paducah there's no B reader in sight. So yes,
20	in that sense in particular it's different.
21	And then the other thing in the current
22	guidelines is lung biopsy, and obviously former

worker program isn't looking at a lung biopsy. 1 They don't do that as part of a screening program. 2 Any other comments at this moment? 3 Okay, so just moving on FWP for pleural disease. 4 I'm sorry, go back to the previous slide. 5 pleural disease due to asbestos. 6 What we require in the former worker 7 program is a history of exposure to asbestos or 8 9 a job title which we expect has exposure to 10 asbestos. And again, a B reading notation of the 11 12 presence of unilateral or bilateral pleural 13 thickening consistent with pneumoconiosis. Pneumoconiosis just means dust disease of the lung. 14 So mind you, we're talking about an 15 16 expert looking at films, just films for occupational lung diseases. 17 And it's most likely that if that person 18 19 sees a single pleural plaque on a side where they also see rib fractures they're probably not going 20 21 to call that a pleural thickening consistent with

pneumoconiosis.

So embedded in this process is an issue 1 that the current program is more explicit about 2 which is this issue of pleural thickening due to 3 trauma or surgery. That's how that's dealt with. 4 So if we could go to the next slide. 5 So, the next series of slides just is 6 7 proposed language subject to change of course. It's a first draft about ways in which defining 8 these entities, the kinds of evidence they're based 9 10 on what would be helpful to the process. The way I think about them is maybe --11 some of these criteria may be within the reach of 12 13 the claims examiner. They would certainly be in the reach of many of the treating physicians. 14 And this kind of specificity should 15 16 certainly be helpful to the CMCs in making decisions 17 about who has and doesn't have any of these entities. 18 And so that's what -- it's not supposed 19 that a claims examiner will necessarily be able 20 21 to understand and apply all of these criteria by

way of their background. But to some extent they

probably could. 1 But in any case the intent is to give 2 3 some greater specificity. And so for asbestosis there are three 4 slides that mimic the current procedure. One is 5 the radiography. The other is the lung biopsy, 6 7 et cetera. But the first one is obviously history 8 of asbestos exposure. We dealt with that in our 9 10 previous recommendations so I'm not going to focus 11 on that. 12 Remember we went over 30 days for 13 mesothelioma, 250 days for the other entities. And then we sent out various job titles or the like 14 to address exposure. 15 16 But on the disease side what we see is 17 the chest X-ray or the CT scan which is the presence of bilateral diffuse interstitial fibrosis which 18 affects any combination of the mid and lower lung 19 And that's what asbestosis is. 20 zones. 21 And that definition, you can look at

a chest X-ray and identify whether the person has

it or not, or the CT scan. 1 And that's in fact what the B reader 2 3 is doing. But it's also what the radiologist is doing and what the pulmonary specialist is doing 4 in looking. And for that matter even the primary 5 care doc should be able to do this if they have 6 7 some experience in reading films. They may not call it asbestosis, but 8 they should be able to -- the definition should 9 10 be able to be used in looking at the X-ray report and seeing whether it's bilateral, is it only in 11 12 the upper zones which wouldn't be asbestosis, and 13 is it a diffuse process as opposed to a specific scar in the mid left lung. 14 And then if the ILO score is used, and 15 16 this is the appropriate definition, it's not expected that the ILO score is going to be used, 17 but it should be in there as a guideline. Question, 18 19 comment? Tori Cassano. 20 MEMBER CASSANO: 21 think the ILO scoring can only be used on B readings. 22 I think it should just be changed if

1	a B read chest X-ray is used then ILO scoring
2	upgraded in one, zero, just, you know, s, t, or
3	u, or passing for clarity.
4	Because should the ILO scoring on a CT
5	scan or a regular chest X-ray.
6	CHAIR MARKOWITZ: Okay, so you're
7	saying if a B reading is performed rather than if
8	ILO scoring
9	MEMBER CASSANO: Yes. If the B
10	reading is performed then ILO scoring greater than
11	one dash zero adds to your, you know, opacity.
12	CHAIR MARKOWITZ: Right. I changed it
13	in my version. I mean, I'm not a B reader, but
14	T will was the TIO agening. Co. that I a little
	I will use the ILO scoring. So, that's a little
15	odd, but we can address that.
15 16	
	odd, but we can address that.
16	odd, but we can address that. Other comments? Next slide. So this
16 17	odd, but we can address that. Other comments? Next slide. So this mimics current language which is the second
16 17 18	odd, but we can address that. Other comments? Next slide. So this mimics current language which is the second diagnostic criteria is what comes out of the FWP
16 17 18 19	odd, but we can address that. Other comments? Next slide. So this mimics current language which is the second diagnostic criteria is what comes out of the FWP program which we went over before is very similar

Now, most people who have scarring in 1 the lung tissue don't come to biopsy. So this, 2 3 I'm showing the current program and the future is going to be quite uncommon. 4 But sometimes if a person has severe 5 fibrosis scarring, or if it's progressed very 6 7 quickly which usually asbestosis doesn't then they may come to biopsy to see if they have something 8 that can be treated. 9 10 So to be complete we need a criterion And it's a simple definition which is 11 for that. when you look at cells what you see is a diffuse 12 13 interstitial process in the lung. I should say that there are -- the 14 pathologists argue about some other things which 15 mainly center on whether they see asbestosis fibers 16 or asbestosis bodies and how much of that do you 17 need. 18 19 But there's general agreement on at least the histologic evidence when you look at cells 20

under a microscope that there needs to be a diffuse

interstitial process, scarring process seen.

21

22

So

1	that's what is here.
2	If you could look to the next slide.
3	Here we favor a history of asbestos exposure.
4	We identify exposure.
5	But actually when you have lung tissue
6	you have the opportunity on asbestos to actually
7	look at whether there are fibers or not.
8	Just parenthetically, this is a
9	complicated subject because some fibers stick
10	around and some fibers don't.
11	Mind you, most people with asbestosis
12	are 20 or 30 years from their initial exposure to
13	asbestos.
14	One type of asbestos, the most common
15	type tends not to concentrate in the lung but to
16	move onto the pleura and elsewhere.
17	So these are kind of complicated
18	topics.
19	But if there is tissue and it can be
20	used to support a claim then you can document
21	exposure, meaning if you're not sure a person has
22	a history of asbestos exposure then you can use

tissue burden of either fibers or asbestos bodies to identify the exposure.

But the history comes first. The history of asbestos exposure is sufficient. And we should probably say this actually that it is recognized as being sufficient to relate the finding of diffuse scarring for the diagnosis of asbestosis, but that in the absence of a history that exposure can be documented through finding of fibers or asbestos bodies.

Now, what you're looking at here on the slide says consistent with excessive asbestos exposure. John Dement wrote in and suggested that phrase consistent with excessive asbestos exposure be replaced by compatible with asbestosis.

Because the examining laboratories vary one to the next. And what one considers excessive is different from what others consider excessive. So he's just suggesting and I think he's right that we should simply say that they find the concentrations of asbestos fibers or asbestos bodies compatible with asbestosis by that very same

1	examining laboratory.
2	That lab has evidence. Relatively few
3	labs do this counting of fibers and so they would
4	have experience with asbestos related disease.
5	So, any comments or questions on that?
6	MEMBER CASSANO: I have just one
7	comment. The only fear I have with this is that
8	a CE in the absence of history of asbestos exposure
9	is going to tell somebody that they cannot accept
10	the finding or something.
11	CHAIR MARKOWITZ: Right. So
12	MEMBER CASSANO: We're not even saying
13	go get a chest X-ray, or go get a CT scan or whatever.
14	The only alternative to the word here of asbestos
15	exposure is a chest X-ray or CT scan according to
16	what we're putting here is a lung biopsy.
17	CHAIR MARKOWITZ: Right, right. So I
18	think it should be clear that the history is
19	sufficient.
20	I don't think I find it hard to
21	believe that claims examiners can direct the
22	medical care of each individual.

1	But I see what you're saying. They
2	could not fully appreciate what it means to have
3	a lung biopsy.
4	So I think I should change the language
5	here to make it clear that the history of asbestos
6	exposure is sufficient, and that in the absence
7	of that history.
8	Well, you know, if you really don't have
9	a history of exposure, even if you have diffuse
10	interstitial fibrosis it's hard to prove your case.
11	MEMBER CASSANO: I agree.
12	CHAIR MARKOWITZ: By the way, let me
13	
14	(Simultaneous speaking)
15	MEMBER CASSANO: exposure is a
16	history of disease that finds it before, correct?
17	(Simultaneous speaking)
18	MEMBER CASSANO: working at a job
19	it's presumed to have had asbestos exposure,
20	correct?
21	CHAIR MARKOWITZ: My thinking is that
22	if they accept our expanded definition of asbestos

1	exposure that we recommended previously that that
2	should capture everybody who's got exposure.
3	MEMBER CASSANO: Okay.
4	CHAIR MARKOWITZ: Mind you, asbestosis
5	in particular takes a fair amount of exposure.
6	It's not occult exposure that causes asbestosis.
7	Mesothelioma, but not asbestosis.
8	MEMBER CASSANO: Right.
9	CHAIR MARKOWITZ: Yes. But it should
10	be clear. Yes, other comments?
11	MEMBER BODEN: Yes, this is Les.
12	First of all, I think that changing excessive
13	asbestos exposure in the way that you suggested
14	is a very sound idea.
15	Also, I'm just wondering whether when
16	we talk about a history of asbestosis exposure that
17	in if we're writing a presumption that someplace
18	in the presumption we refer specifically to what
19	we mean by that.
20	CHAIR MARKOWITZ: The history?
21	MEMBER BODEN: Yes.
22	CHAIR MARKOWITZ: Yes.

And presumably the 1 MEMBER BODEN: history also includes -- I'm trying to remember 2 how it was worded before because I thought the 3 wording was good, that it was a history, or having 4 a job or task that was considered to be exposure, 5 to have exposure to asbestos. 6 7 (Simultaneous speaking) MEMBER CASSANO: So you could actually 8 9 have presumptions. You could have two 10 presumption of exposure and we could list it as a presumption of exposure which is sort of what 11 we did when we talked about history of asbestos 12 13 exposure. We might actually call it a presumption 14 It should be presumed that a person of exposure. 15 16 is exposed to asbestos if they have worked in whatever facilities, or done whatever jobs over 17 a period of seven years for asbestosis. 18 19 MEMBER BODEN: Right. 20 CHAIR MARKOWITZ: Well, yes, in April 21 we approved the exposure presumptions. 22 We just want to make MEMBER BODEN:

1	sure we incorporate it in this document.
2	MEMBER CASSANO: Maybe we should say
3	an alternative for history, and we tell that history
4	of exposure here we should say as per whatever the
5	document is that contains our previous
6	recommendation on how you define history of
7	asbestos exposure.
8	CHAIR MARKOWITZ: Right. That's
9	good. In fact, we might even repeat it here. I
10	have a slide with in case they don't accept our
11	previous recommendations, right?
12	(Laughter)
13	CHAIR MARKOWITZ: And that could
14	happen, that could happen.
15	MEMBER BODEN: Right, in which case you
16	can't refer back to it.
17	CHAIR MARKOWITZ: Exactly. Rejected
18	recommendations. Okay, fine.
19	MEMBER WHITLEY: Garry here. What
20	they're going to do a claims examiner going to
21	do automatically is they're going to go to the SEM
22	database. That's where they're going to get their

history of exposure. 1 So if you were a pipefitter, asbestos 2 worker, that stuff, you're fine. If you look at 3 the buildings that says they contain asbestos, they 4 show all of them in the whole plant. 5 You go down to a supervisor or even 6 7 though he worked in that building with a crew every day, if you go down to a supervisor and look up 8 to see if he was exposed to asbestos even though 9 10 he's in that building it will say no. No, no. Claims examiners are going to use the 11 12 SEM database to help you, but they're also going 13 to use it against you if you're not listed in it. CHAIR MARKOWITZ: Yes, I'm just trying 14 bring recommendation on asbestos 15 up our 16 exposure. 17 This is from our recommendation from April which is on 18 the exposure side. We recommended at least 250 days of exposure, 19 20 title, on the presumption side any maintenance or 21 construction worker. And this would be exposure

prior to 2005 with a minimum of 15 years.

1	Anybody who doesn't make that
2	presumption would be individually evaluated.
3	So I don't know, Garry, if that
4	addresses the scenario that you raised here or not.
5	But that was our discussion of documenting
6	asbestos exposure previously, at least for
7	asbestosis.
8	MEMBER WHITLEY: Garry here. I think
9	the only way you can do it properly because you're
10	going to be fighting against the SEM database.
11	So, if you're not listed there you're going to have
12	to prove it otherwise.
13	CHAIR MARKOWITZ: Right. You know,
14	again, for asbestosis you need a fair amount of
15	exposure to asbestos. So it should be provable.
16	And I'm not talking about industrial
17	hygiene data. I'm talking about description of
18	tasks, description of work that a person did, job
19	title. In this one we're okay.
20	So let's move onto the next slide.
21	MEMBER SILVER: Before we move on, this
22	is Ken. The lung tissue burden can also be

1	demonstrated on autopsy tissue.
2	CHAIR MARKOWITZ: Yes. It's not
3	specific here. It could be a biopsy or autopsy.
4	MEMBER SILVER: Thank you.
5	CHAIR MARKOWITZ: Next slide. Here's
6	for asbestos pleural disease, a history of asbestos
7	exposure. Again that harkens back to our previous
8	recommendation.
9	And then finding on chest X-ray or CT
10	a unilateral or bilateral pleural thickening, or
11	plaques that's not readily explained by another
12	cause.
13	And that should be sufficient for most
14	doctors to be able to make a decision as to whether
15	it's asbestos related pleural thickening or not.
16	
17	It gets tricky when a person has had
18	heart surgery and you see diffuse or relatively
19	extensive pleural thickening at the bottom of the
20	lung on one side, and was that asbestos exposure
21	or was that the surgery.
22	And doctors may disagree, but no amount

1	of definition is going to resolve that. That's
2	just judgment.
3	MEMBER CASSANO: Going back to the
4	prior slide. You don't have to go back, but just
5	thinking about the prior slide why can't somebody
6	if somebody has fibrosis but no history of
7	asbestos exposure and they have pleural plaques
8	with no other explanation for them.
9	I mean I have always been told and have
10	always considered pulmonary fibrosis and pleural
11	plaque as sort of capping or asbestosis.
12	So why can't we use the presence of
13	pleural plaque with the fibrosis as definitive of
14	asbestosis?
15	I know there's some other things that
16	can do that, but not a whole heck of a lot.
17	CHAIR MARKOWITZ: Yes. That's a good
18	idea. Let me I will draft some language that
19	addresses that.
20	Again, it takes a lot of asbestos
21	exposure to get asbestosis.
22	MEMBER CASSANO: Yes.

1	CHAIR MARKOWITZ: And so it's unlikely
2	to be occult, you know, or not noticed. But if
3	a person really isn't in the right job title,
4	doesn't report it, but has pleural plaques and
5	interstitial fibrosis then I would probably lean
6	towards asbestosis as you say.
7	So let me add some language to reflect
8	that. Which we don't have to draft here because
9	we're just working this up, but when we meet.
10	I'll circulate another version of this
11	before the meeting in October or November.
12	MEMBER CASSANO: I could give you some
13	language, but you probably will be better at it
14	than I.
15	CHAIR MARKOWITZ: I mean, I'll draft
16	it and everybody can look at it and chime in. Or
17	if you want to send over language that's fine too.
18	Whichever. That works. Other comments?
19	Okay, so let's go let's see, we're
20	at pleural disease. Any comments on this
21	particular slide? You notice we're not
22	quantifying how much pleural thickening. We are

1	leaving it open as whether it's one side or both
2	sides. And I think that's appropriate to not get
3	any more specific than this.
4	MEMBER VLIEGER: This is Faye. I have
5	a question and it comes from the fact that I have
6	a recent claimant that went through the IH in D.C.
7	who we interviewed at our meeting there.
8	And this person was an asbestos
9	insulator, but not for 15 years. He was there for
10	17, 18 months, but he was an asbestos insulator.
11	During the time period where they
12	weren't required to wear masks or alternative air.
13	And the IH said that his exposures would
14	have been incidental and infrequent and thereby
15	sending it to a CMC who of course was not going
16	to disagree with the IH.
17	And of course the answer came back that
18	his lung condition, not asbestos disease, but his
19	lung condition was not caused or contributed to
20	his asbestos exposure.
21	How are we going to get away from this
22	being sent to the IH who presumes, or has to presume

1	that the person worked or was exposed to asbestos?
2	I don't know how we're going to get away from that
3	part of the law that says you have to prove exposure.
4	You know, you have to prove exposure.
5	CHAIR MARKOWITZ: This is Steven.
6	Again, if our prior recommendation is accepted for
7	that outcome, either pleural thickening, or pleural
8	plaques, or asbestosis, if a person has 250 days
9	of exposure certainly that person was an insulator,
10	so they're like number one on the job title list.
11	If they had 18 months of work then they
12	would make it as a matter of presumption.
13	MEMBER VLIEGER: You would think that,
14	but the other thing that of course they threw out
15	there again was, well, you know, smokers have this
16	happen to them too, therefore that in a short period
17	of work this couldn't have happened.
18	I don't know how we can get away from
19	an IH and a CMC doing the same song and dance that
20	they haven't already done here. If it gets sent
21	to a CMC.
22	CHAIR MARKOWITZ: Well, there's no

amount of guidelines that we can recommend that 1 would get around the problem of misapplication or 2 incorrect decisions. 3 Although, another recommendation that 4 we're going to take a look at, there are a number 5 of CMC decisions or recommendations or opinions 6 7 and then look at their level of accuracy. Okay, well I'm just MEMBER VLIEGER: 8 trying to figure a way in this wording that it 9 10 doesn't have to go out to an outside source. So far these are still recommendations I understand, 11 12 but somewhere in the wording it's like well, I know 13 this is presumptive, but we haven't said don't do the other things. 14 They still always have the option of 15 16 doing the other things. Yes, but we've also 17 CHAIR MARKOWITZ: in other conversations have been circumspect about 18 the claims examiner making decisions that they're 19 not really qualified to make. 20 21 But you know, the idea of adding more 22 specific diagnostic criteria would also help the

treating physician because there are guideposts the treating physician could -- this is how the program looks at evidence for these entities. It's now more specific than it was previously.

And then they in their letter if it's true or cite that, okay, my decision on asbestosis is based on review of the chest X-ray which showed bilateral and diffuse interstitial fibrosis in mid and lower lung zones.

And the CE then should be able to match up what the treating physician has said with the evidence that we're recommending and say yes, that's the case. No need to send to the IH or CMC. We're done.

I think the added specificity would allow both the treating physician get a better sense of what's required, but also allow the CE to make a decision and not do what you're worried about which is sending it to an IH or CMC who's going to make the wrong decision. Does that make sense?

MEMBER VLIEGER: It does. I guess part of my frustration is we work on these things

1	and it's all logical and good, and then back in
2	the trenches we're still dealing with the idiocy.
3	CHAIR MARKOWITZ: Well, you know, the
4	application, should they accept these
5	recommendations, the application, we should get
6	around to figuring out how to help monitor the
7	application of these things so that they're applied
8	appropriately.
9	MEMBER SILVER: Ken Silver here. We
10	might start generating a list of issues that we
11	want to remark upon with great emphasis in our
12	accompanying rationale.
13	The pathogenicity of plaques in
14	asbestos, what smoking does and does not contribute
15	to lung cancer and fibrosis as I understand it.
16	And maybe the phenomenon of short-term
17	high-level exposure causing chronic asbestosis
18	years later.
19	I think findings back from the late
20	seventies, early eighties of lung bumps in an
21	amosite plant you know, still cited.
22	So if you put a big emphasis on that

1	in the rationale at least advocates can say look,
2	we told you so.
3	CHAIR MARKOWITZ: Also the rationale
4	would be accessible to the physicians who are part
5	of the process meaning the treating physician and
6	the CMC. So it would be useful.
7	Yes, I haven't transferred the
8	rationale but when I do and send it around, if it
9	doesn't have those points, Ken, throw them in there.
10	MEMBER SILVER: Okay.
11	CHAIR MARKOWITZ: Other comments on
12	this? So let me see. It's 2:15. Do people want
13	to take a five-minute break? I have three or four
14	more slides. But if people want to take a break
15	we can.
16	MEMBER BODEN: I'm okay going on, but
17	maybe other people
18	MEMBER CASSANO: I'm okay.
19	CHAIR MARKOWITZ: Okay. So let's
20	continue then. Okay, next slide then.
21	So this is for pleural effusion. This
22	is a very uncommon condition and I'm a little

1	surprised actually to see it in the language of
2	the manual.
3	But there's no definitive way of making
4	the diagnosis. You need the history of exposure
5	and then you need an unexplained pleural effusion.
6	Even in such a population 9 times out
7	of 10 that pleural effusion is going to be caused
8	by something else like heart failure, or
9	inflammation, or very common causes.
10	So this definition should be
11	sufficient. I don't think the claims examiner is
12	really likely to be able to make this call, but
13	treating physician and the CMC certainly could.
14	Because if a person has inflammation
15	infection or a heart failure that should be pretty
16	apparent from the medical record or from examining
17	the person.
18	More than a dozen claims for this I'd
19	be surprised. It's a very unusual condition
20	especially these days.
21	Any comments on this? Okay. So let's
22	go on to the next slide.

1	Okay, so this is important because
2	these are common outcomes. And these are all the
3	cancers that are recognized as being related to
4	asbestos.
5	So how do we want the claims examiner
6	to look at a case. Generally they are looking
7	probably at present and they should look for
8	pathology reports because there's either a biopsy,
9	or autopsy, or surgery in which they've taken a
10	whole bunch of tissue.
11	And it says on the pathology lung cancer
12	it says mesothelioma or cancer of the ovary or
13	larynx. It won't say asbestos, but that's not
14	needed for this process.
15	The history of exposure comes from
16	different kind of evidence.
17	There are some instances, particularly
18	in older people, who aren't well enough to undergo
19	a biopsy, or surgery, or there's no point in doing
20	surgery.
21	They may not come to autopsy. And it
22	doesn't happen very often but it does happen in

which case the physician is left trying to make 1 the best judgment without having tissue whether 2 3 the person has a cancer and what the cancer is cancer 4 of. And I think the claims process -- I'm 5 not sure how it works now in terms of these claims, 6 7 but it has to recognize this group of presumed diagnosis. 8 And this is not something that the 9 10 claims examiner would do. It is something that 11 the physician would do. 12 And that is just by way of example if 13 a person comes in, they've lost weight, they're short of breath, they have fluid in their chest 14 and they have a big mass coming from the pleura 15 16 then chances are that's mesothelioma. 17 Or they have a big mass in the lung and no one's going to do surgery, it's too risky to 18 do biopsy, that's going to be a lung cancer with 19 90 percent certainty. 20 21 So this group should be specified in 22 the claims examination process.

Or a death certificate that mentions 1 one of these entities somewhere on the death 2 3 certificate. Usually not very far down because at least for mesothelioma, cancer of the lung, 4 cancer of the ovary people usually die of those 5 entities. 6 7 MEMBER CASSANO: Do we need to say something about with or without looking for a 8 history of smoking? Just because I see a lot of 9 10 times that the person smoked, they've got lung 11 cancer, it's due to smoking, it's not due to 12 asbestos. 13 CHAIR MARKOWITZ: Yes, we should put that in the rationale. Rachel has told us that 14 the process doesn't recognize or take into account 15 16 smoking, but CMCs presumably read this. We're not quite sure whether 17 follow everything in the program. And the treating 18 19 physicians wouldn't be downed by this either. in the rationale it 20 should 21 explicit. Smoking does not contribute to

Smoking does to lung cancer, but

mesothelioma.

1	in a way that exacerbates the asbestos exposure,
2	et cetera. We'll put that in the rationale.
3	MEMBER CASSANO: Okay, thanks.
4	CHAIR MARKOWITZ: So my question
5	overall about these, is this added level of
6	specificity and pointing out the relative utility
7	of different ways of diagnosing or sources of
8	evidence, would this represent an improvement over
9	the current process.
10	MEMBER CASSANO: I think if they enlist
11	the doc I mean, the doctor would be able to
12	determine that.
13	MEMBER VLIEGER: I'm sorry, are we on
14	slide 20? This is Faye.
15	(Simultaneous speaking)
16	MEMBER VLIEGER: on the WebEx.
17	CHAIR MARKOWITZ: Yes, we're on 20.
18	We're on the cancer list. Yes.
19	MEMBER VLIEGER: So as far as all of
20	this it looks pretty much normal the way it runs
21	right now. I don't see any problem with it.
22	We don't usually have pathology. We

could make a comment on it on the death certificate.

But there again we run into the same problem on death certificates as we do with diagnostic paperwork from the physicians here. Unless it's been heavily charted and documented they're not going to make any asbestos diagnosis on a death certificate unless there's been an autopsy and those are not common.

CHAIR MARKOWITZ: So Faye, does that mean if a person has a documented history of asbestos exposure it's recognized by the claims process, but then has lung cancer on the death certificate but it doesn't say anything about asbestos related lung cancer, that that wouldn't necessarily be accepted?

MEMBER VLIEGER: That's correct. That's correct. I have a case right now where the person was in the hospital, had recently been diagnosed with multiple myeloma, had one chemo treatment, went to the hospital with a blood clot and the death certificate says he died from a blood clot. Does not mention the mesothelioma. So the

death certificate is not useful at all unless it's 1 specific. 2 3 Even if it's secondary or tertiary cause, it has to be on the death certificate. 4 But we have the physicians at the 5 largest hospital in the area here for the Tri-Cities 6 7 that they only put the most immediate cause of death and then to try and get a death certificate amended 8 they refuse. So you have to go through the coroner 9 10 and that can take up to a year because the coroner 11 is busy with the most recently dead, not the more 12 longer dead. 13 And in the two cases I had to have death certificates amended it took more than a year. 14 CHAIR MARKOWITZ: Right. Well, 15 Wow. 16 the problem is not DOL or the program, the problem 17 is the healthcare system that doesn't get the death certificate right. 18 19 Well, yes, that's the MEMBER VLIEGER: 20 problem. What I see more of a problem is that DOL 21 has the physicians running scared because the 22 program guidelines are not clear.

And there are no pamphlets out to the 1 say this is what I accept for 2 doctors that 3 mesothelioma. This is what we accept for COPD. This is what we accept for asthma. 4 The department has failed to do that 5 probably to their own benefit. So the doctors take 6 7 two steps back for a couple of reasons. First of all they did not go to school 8 to play legal beagle. 9 10 Secondly, the state labor and industry's claims system has all of them running 11 scared that they're going to have to spend a day 12 13 of clinic time in depositions. So the Department of Labor program 14 because it doesn't specify and it doesn't provide 15 16 an easy way for them to understand what's going 17 they think it's like every other worker compensation program which is going to require them 18 19 to not have office time for patients, but to have to do legal maneuvers. 20 21 So, I think the department could do some 22 things to improve this, but right now no, they don't

1 make it easy. And by the same token as when we look 2 on the CMC side of things the CMCs are barely vetted. 3 And as you saw in the decisions we reviewed don't 4 even follow program quidelines because there's no 5 clear program guidelines given to them either. 6 7 CHAIR MARKOWITZ: If we can develop some consensus diagnostic criteria I think it will 8 be useful by all elements, the treating physicians, 9 10 the CMCs, the claims examiners. This should provide some greater basis 11 12 for making decisions and more uniform as well. 13 Doctors not wanting to participate in legal processes, compensation systems and the like, 14 that is a huge problem everywhere in relation to 15 16 workers compensation, any federal compensation program, tort litigation, you name it. 17 It's just 18 universal. 19 You lecture first-year medical students and mention lawyers and they boo you. 20 21 It's a problem. 22 Steve, tangential to MEMBER CASSANO:

A recommendation that we could make is that 1 in these areas where there's large numbers of 2 3 claimants, et cetera, that there should be some program, it doesn't have to be -- somebody should 4 be going to the hospitals and maybe doing grand 5 rounds, or even a lunch and learn if you will on 6 some of these issues for the local physicians inside 7 -- how to fix it. 8 It's obviously outside of our purview, 9 10 but maybe it's not. Maybe it's something we could do when we do one of these meetings. 11 Have a two-hour session for local docs in a meeting to 12 13 talk about some of these issues. The Department of 14 CHAIR MARKOWITZ: Labor --15 16 MEMBER CASSANO: I don't know if that's in our purview or not, but it should be done by 17 somebody. 18 19 CHAIR MARKOWITZ: The Department of Labor has a joint task force with NIOSH and with 20 I think it was the Ombudsman's Office to do 21 DOE. 22 these public meetings to discuss compensation

1	program, former worker program and other things.
2	And conceivably they could engage the
3	former worker programs to do this kind of medical
4	education.
5	MEMBER CASSANO: Yes.
6	CHAIR MARKOWITZ: Part of the problem
7	is frankly we don't think the doctors would show
8	up because they're not all that interested.
9	MEMBER CASSANO: Well, unless somebody
10	gave them CME credits. Then they would.
11	MEMBER SILVER: This is Ken Silver.
12	Going back to this slide. Faye if this were adopted
13	the connecting word is "or." Would you have been
14	able to use number 2 in your mesothelioma case where
15	the death certificate said blood clot? Would you
16	be able to win the claim based on number 2 on this
17	slide?
18	MEMBER VLIEGER: If there's clinical
19	evidence then they would be eligible for Part E.
20	But under Part E the death certificate wouldn't
21	match the clinical.
22	And so in order to qualify for survivor

benefits the death certificate, the reason they died has to be a covered condition or a later covered condition.

And the death certificate would not match in this case and therefore there wouldn't be no survivor benefit.

The only caveat to that is if there was a claim in place at the time of death and the department was dawdling and the person died, then the Russero ruling would come into play with the survivor claim where they would be eligible for benefits.

But that only applies if there is a claim in process that the Department of Labor has administratively dawdled on. And then Russero would come in play because the family would be eligible for the claims that would have been eligible while the claimant was alive.

In most cases when you're dealing with a claim filed posthumously and the death certificate does not match for a condition covered under Part E, and that's what asbestos would be,

then you would either have to get an autopsy done, 1 or you would have to have your death certificate 2 3 changed. And both of those are similar to having 4 baby elephants. 5 I believe diagnostic MEMBER SILVER: 6 criteria would work for causation for like a wage 7 loss claim, or coverage in medical benefits, but 8 then for survivors claims someone would have to 9 10 administratively extend our logic and override the death certificate requirement. 11 12 MEMBER VLIEGER: Exactly. 13 MEMBER SILVER: Okay. CHAIR MARKOWITZ: This language we're 14 looking at actually would provide the basis for 15 16 that, a rational medical basis for that decision. 17 MEMBER SILVER: Right. 18 MEMBER VLIEGER: Yes. If there's 19 enough medical evidence that it's pretty clear-cut the coroner doesn't have any problem doing the 20 21 But we have to have the documented change. 22 medical.

I haven't had to use an autopsy result to change a death certificate. I have one pending right now and I don't know what the outcome's going to be.

MEMBER CASSANO: So if it requires a medical opinion working with a -- if I'm understanding this right it works like the ABD I work with it would be a medical opinion that states that if it doesn't at the cause of death then the mesothelioma despite what -- that the contributory cause of death was mesothelioma despite what is on the death certificate. Am I correct, Faye?

MEMBER VLIEGER: That or enough evidence that they were diagnosed with it prior to their death. And as long as it was being actively treated it should have been listed on the death certificate.

MEMBER CASSANO: If it wasn't on the death certificate then -- we may be able to come up with some language that basically says if there is current evidence yada yada yada at the death certificate that's not included as a contributory

1	secondary or contributory cause then the claims
2	examiner should forward it to the CMC for a
3	decision.
4	I think that would work. And then we'd
5	give the CMC guidance on that.
6	MEMBER BODEN: Can I just ask a
7	question about this last slide just to clarify.
8	So these are diagnostic criteria for example for
9	cancer of the lung, not necessarily asbestos
10	related cancer of the lung.
11	CHAIR MARKOWITZ: Right.
12	MEMBER BODEN: Right? Okay. So if
13	then one wanted to tie it to occupation one would
14	need additional exposure evidence.
15	CHAIR MARKOWITZ: Right.
16	MEMBER BODEN: Yes? Okay. Just to
17	clarify for me. I wasn't sure I understood that
18	right.
19	CHAIR MARKOWITZ: Right. And for the
20	other conditions in every instance we mentioned
21	the history of asbestos exposure because they were
22	asbestos specific conditions like asbestosis,

1	pleural disease or the like.
2	But here I could have added a slide to
3	say related to asbestos requires fulfilment of the
4	criteria plus a history of exposure.
5	MEMBER CASSANO: Well, what about
6	mesothelioma just for relevance.
7	CHAIR MARKOWITZ: You know, actually
8	in our recommendation for mesothelioma we said 30
9	days and a minimum of the right job title or a
10	history of exposure or the like.
11	So there should be some documentation
12	of the asbestos exposure. But it usually doesn't
13	require much.
14	MEMBER CASSANO: Okay.
15	CHAIR MARKOWITZ: Tori, getting back
16	to your point, your suggested language, if you want
17	to draft something and send it to me.
18	MEMBER CASSANO: I believe that's about
19	what I was going to say. Oh it was about pleural
20	plaque plus sarcoidosis.
21	CHAIR MARKOWITZ: No, this was about
22	the issue that Faye was raising about the use of

1	clinical information
2	MEMBER CASSANO: Okay, so
3	CHAIR MARKOWITZ: for a physician
4	to opine on a cause of death when the death
5	certificate doesn't mention.
6	MEMBER CASSANO: Okay. I will do
7	that.
8	CHAIR MARKOWITZ: Yes. I mean, it's
9	a bit of a tough hurdle because you're seen as sort
10	of second guessing the doctor who actually attended
11	the death and filled out the death certificate,
12	but it's worth putting in there I think.
13	MEMBER CASSANO: You know, I see a lot
14	all the time it's cause of death heart attack.
15	Well, the heart attack is secondary to the fact
16	that the person had pleural or whatever, but
17	the final event is always the heart stops.
18	So, I don't think it's difficult and
19	I think once it's explained, the claims examiners
20	and to the agency that it could be I don't think
21	it's going to be difficult to make it happen.
22	CHAIR MARKOWITZ: The other thing of

1	course is that frequently the physician filling
2	out the death certificate is the person who happens
3	to be in the hospital when the person died. And
4	they're typically being a resident.
5	So they may be covering for somebody
6	else and may not even know the patient or what the
7	patient's illnesses are.
8	So that's not apparent to the outside
9	world, but it generally happens.
10	MEMBER CASSANO: Yes. Okay, so I can
11	do that.
12	CHAIR MARKOWITZ: Okay, so if we're
13	done with asbestos let's move onto the last slide.
14	And here I'm not expressing an opinion,
15	I'm just raising issues. I went through the claims
16	the procedure manual for other conditions that
17	it mentions.
18	It does mention at the end of chapter
19	2 or whatever the new chapter is Parkinsonism
20	without saying much about it other than treating
21	the various synonyms for Parkinsonism meaning
22	Parkinson's disease, Parkinson syndrome,

Parkinsonism to treat them as the same. 1 doesn't weigh in in terms 2 of 3 exposures. And then there's an exhibit which is 4 an attachment or an appendix to the manual which 5 lists -- which is an old thing I think from the 6 7 beginning of the program which lists a number of different entities including peripheral 8 neuropathy, damage to the nerves of the arms and 9 10 legs caused by a toxin. It also mentions something called toxic 11 12 encephalopathy, chronic toxic encephalopathy which 13 is brain damage due to chronic exposure to certain toxins such as metals or solvents in particular. 14 But it doesn't really go into any detail. 15 16 And then also it just very briefly mentions chronic kidney disease. 17 18 I don't know that there are many claims 19 for these conditions so it's hard -- we can ask DOL if there are, because if there are not I don't 20 21 think there's any rationale for trying to design

presumptions.

Well, I just wonder 1 MEMBER CASSANO: if the reason there aren't any claims for them is 2 3 that people don't know that organic solvents, toxic encephalopathy or Parkinson's disease. 4 And the literature is pretty replete 5 now with both epidemiologic and toxicologic studies 6 7 that tend to prove that association. I think the other one might be -- and 8 again, organic solvents, specifically benzene --9 10 I don't know how many of these people were exposed to benzene, and acute myelogenous leukemia. 11 12 I don't think we should use how many 13 claims are there. I mean, I don't want to open up another can of worms for the agency either, but 14 people that have diseases that are related to their 15 16 work should be compensated. But I don't think we should start with 17 I think we should look at the how many claims. 18 19 form and see what the major toxicants are in the workplace. And if we see major toxicants that we 20 21 know definitively cause disease then those are

easily turned into presumptions.

1	And I just mentioned the two of them.
2	There's benzene in AML and Parkinson's and both
3	manganese if there's an extension of manganese,
4	I don't know if there is.
5	So, primarily two to use.
6	MEMBER VLIEGER: This is Faye. DIAB,
7	the board that I still chair on though it's gone
8	kind of dark did a list of diseases most likely
9	denied by the department. I can resurrect that
10	list and send it.
11	But of the things that were more
12	routinely denied was peripheral neuropathy,
13	Parkinsonism, dementia, chronic encephalopathy,
14	toxic encephalopathy.
15	So I can resurrect that list. But what
16	we had done was look at the statistics from the
17	Department of Labor and look at the things that
18	were most likely denied.
19	So if you want I can resurrect that and
20	send it out.
21	CHAIR MARKOWITZ: Sure.
22	MEMBER VLIEGER: All right, thank you.

CHAIR MARKOWITZ: The issue of whether 1 they should come to presumptions depends on a number 2 3 of factors like is there enough information to make decisions. 4 There may be that a number of these 5 different conditions, either a high denial rate, 6 7 or a fair number of denials, not referring to rate, that the issue of not lack of presumptions but the 8 issue is that the SEM is incomplete or inaccurate, 9 10 or the claims process doesn't recognize certain 11 aspects of these diseases. diabetes 12 if а person has the 13 neuropathy is always chalked up to the diabetes and never to the toxin. 14 That's separate from the issue 15 16 whether there should be presumptions. 17 So I guess we may need to figure out what the particular issues for these conditions 18 19 first before deciding whether they're are 20 appropriate to try to elaborate presumptions. 21 MEMBER CASSANO: You mean as far as DOL 22 is concerned, as far as the exposure is concerned,

1	or what?
2	CHAIR MARKOWITZ: Well, it could be
3	exposure, it could be the diagnostic criteria.
4	It can be any aspect of the process.
5	MEMBER CASSANO: Okay.
6	CHAIR MARKOWITZ: But that may involve
7	I mean, if we believe that toxic neuropathy might
8	be an issue that's not that there is some
9	suspicion it isn't being addressed properly then
LO	we could look at a certain number of cases of toxic
L1	neuropathy denied and accepted and see how the
L2	decisions are made and whether we think there's
L3	any room for improvement.
L4	And that's what occurred before the
L5	issue of developing presumptions.
L6	MEMBER CASSANO: Yes. We could look
L7	at the Parkinson's disease too because I don't know.
L8	I mean, I'm not organic solvents have to be
L9	a huge exposure issue in this area. I am assuming
20	that. I don't know if that's true.
21	Can somebody educate me on that?
22	CHAIR MARKOWITZ: Solvents?

1	MEMBER VLIEGER: I'm sorry, is the
2	question that we're
3	MEMBER CASSANO: Solvent exposure has
4	to be there in these facilities.
5	MEMBER VLIEGER: So I don't know if
6	anyone goes home and plays with them on purpose.
7	MEMBER CASSANO: Excuse me?
8	MEMBER VLIEGER: Yes, it would have to
9	be occupational. Like I said, I don't know of
10	anybody that goes home and plays with these things
11	on purpose.
12	MEMBER CASSANO: Yes, I mean people
13	work on their own cars, they use degreasers, they
14	ship furniture at home, et cetera. So some of it
15	can be from home, but usually that's incidental.
16	It's not chronic low-level or chronic moderate
17	level.
18	So, I think we need to know how I
19	think looking and that's something I guess
20	Rosie's group and my group could do once we get
21	past our next meeting is start looking at these
22	neuropathy and the Parkinson's disease claims and

see whether the evaluation specifically by the CMC 1 and/or the industrial hygienist are appropriate. 2 I hate to make more work for Rosie. 3 I think that makes 4 CHAIR MARKOWITZ: I think we need to understand some of the 5 issues better with some of these entities before 6 7 deciding which recommendations we might make. MEMBER CASSANO: I was only looking at 8 it from out of these things what is the definitively 9 10 proved as a causal. That's all I was looking at. 11 I wasn't looking at it from the perspective of 12 the agency. 13 MEMBER SILVER: Kidney disease This is Ken Silver. interesting. In that there's 14 a lot of diabetes out there and there's a lot of 15 16 uranium at these sites and many organic chemicals have been shown to cause various kinds of kidney 17 damage in animals in particular. 18 And there's evidence of synergistic 19 effects. 20 21 So if the statistics from DOL suggest 22 that kidney disease looms large, the issue is them

1	getting people to take a look at that.
2	MEMBER CASSANO: Well, certainly, yes,
3	kidney disease and adrenal carcinoma is another
4	one related to organic solvents. Specifically
5	CTE.
6	MEMBER SILVER: And we did look at a
7	claim that was pretty much a slam dunk a few months
8	ago. It was paid, but teasing apart kidney
9	disease due to diabetes versus uranium exposure.
10	There were two cases at Los Alamos.
11	Both had happy endings for the claimants. But it's
12	a very small sample.
13	A much larger n in the DOL system.
14	MEMBER CASSANO: That's part of the
15	problem with how we look at these cases is that
16	they're not randomly picked. And I think we saw
17	that when we went to Seattle.
18	So, I'm not sure if there's some way
19	to get a list of what's been adjudicated this month
20	and randomly pick rather than having each district
21	office pick the ones they want to send to us.
22	Faye, you may want to elaborate on that

1	a little bit more based on our meeting in Seattle.
2	But we'll deal a lot more with that on Tuesday
3	I think is when we meet, correct?
4	MEMBER VLIEGER: The 27th, isn't that
5	Monday?
6	MEMBER CASSANO: The 27th.
7	CHAIR MARKOWITZ: That's Tuesday,
8	11:30 a.m.
9	MEMBER VLIEGER: Yes, Tuesday. This
10	seems, and I don't know how random random is when
11	you're doing a specific district office and we're
12	looking at claims from that district office.
13	It just seems that the claims process
14	is becoming so convoluted that anything we can do
15	to keep it from becoming as convoluted as it is.
16	Maybe taking out as much as possible
17	the individual decision-making.
18	I agree that when we went to Seattle
19	the people seemed to generally know what they
20	were doing. What we were working with was pretty
21	picked.
22	CHAIR MARKOWITZ: Pretty what?

Yes, there wasn't 1 MEMBER CASSANO: anything really controversial that we saw. 2 3 one case that they actually agreed was adjudicated incorrectly and they were going to take another 4 look at it. 5 So I'm not sure if we saw the best of 6 7 what there was, or whether -- I know it wasn't a random sample because they picked them based on 8 their medical interests from the supervisor's 9 10 position. I don't know that we could get really 11 12 down and dirty in looking at these, other than to 13 say send me a list of numbers of all the Parkinson's disease cases who have been adjudicated this month 14 and I'll just randomly pick numbers. 15 16 I don't need the files initially, I just need the case numbers and I'll just randomly pick 17 numbers, or somebody will randomly pick numbers. 18 19 And that's a little bit better than somebody --I'm hoping they're not cherrypicking them, but they 20 21 probably are a little bit.

MEMBER WHITLEY:

22

Ιf

This is Garry.

1	you do Parkinson's you need to do current cases
2	because if you go back three to five years ago they
3	didn't pay for Parkinson's at all.
4	MEMBER CASSANO: Right. Because
5	there was not a lot of definitive evidence that
6	organic solvents caused it.
7	MEMBER WHITLEY: Right. But recently
8	they have been paying for a few at least in our
9	area that I see Parkinson's.
10	Neuropathy they used to not pay at all.
11	Now they're paying some neuropathy cases if
12	there's no signs of diabetic even in the family
13	of diabetes even in the family.
14	If there's any signs of diabetes
15	they'll throw it out in a hurry.
16	The one they won't touch is pancreatic
17	cancer. I don't know anybody that's been paid for
18	pancreatic cancer. I could be wrong, but everybody
19	I know, they get back a letter that says there's
20	no evidence of any chemicals that cause pancreatic
21	cancer.
22	MEMBER VLIEGER: To clarify, that's

only under E for toxic exposure, not Part B. 1 There is some limited MEMBER CASSANO: 2 3 evidence for I forget what it is, an association, but it's pretty darn weak for pancreatic cancer. 4 Unless -- could arguably disagree I don't think 5 with not compensating pancreatic cancer. 6 7 just not enough -- there's nothing practically out there about toxic etiology of pancreatic cancer. 8 From what I've been able to see. 9 10 CHAIR MARKOWITZ: I agree. 11 MEMBER SILVER: So in terms of 12 process we could ask DOL for more systematic 13 sampling, or counts of cases where these issues 14 may come up. Another thing we might do is if the 15 16 advocates who are listening to weigh in with, you know, helpful one-page emails to flesh out where 17 we might be useful on developing new presumptions. 18 19 MEMBER VLIEGER: I want to agree with 20 Garry that Parkinson's disease even with adequate 21 information is a hit or miss entity to get it

accepted.

1	And recently I had a case accepted that
2	had been pending for more than a year.
3	I cannot tell you the difference
4	between the information provided in that claim and
5	the other claims that got accepted and five others
6	got denied.
7	It just seems very eclectic with what
8	they accept and don't accept. And it hinges on
9	the contract medical consultant report.
10	MEMBER CASSANO: Probably hinges a lot
11	on the knowledge of the CMC.
12	MEMBER VLIEGER: I'm not willing to
13	cast any aspersions but I totally agree with you.
14	MEMBER CASSANO: Because and it
15	changes every month practically.
16	CHAIR MARKOWITZ: So we have just five
17	minutes left, and I wanted to try to see if we could
18	figure out what our next steps are.
19	And I would actually think that the
20	report that Faye talked about a while back which
21	was cases frequently denied, even though it would
22	you couldn't publish the results in a journal

it might actually be useful to us. 1 Because we certainly want to try to pick 2 3 up on diseases that were controversial but where 4 there were enough cases that our presumption would help more than a couple of people. 5 And then if we pick diseases that we 6 want to look at next that we ask for a listing of 7 all the cases in a certain time period where this 8 disease was at issue, just the case numbers, and 9 10 then we pick a random sample and take a look. 11 MEMBER CASSANO: I think that's a good idea. 12 13 MEMBER VLIEGER: This is Faye. a copy of the data that was assembled by the 14 Institute of Medicine for the program under -- by 15 16 request from the Department of Labor. And I'm going to be sending that to 17 Carrie shortly. 18 19 In the top 10 are a number of malignant neoplasms of different places. 20 But something that 21 is commonly denied as emphysema. I've seen a 22 turnaround in that.

1	So I will send this out. And this is
2	from IOM was contracted by the Department of
3	Labor. So this is from 2011 but I know I've got
4	another list that DIAB and NTAC put together as
5	part of what we would need to recommend things to
6	the Department of Labor.
7	I'm sorry, I'm still looking for that
8	one.
9	MEMBER CASSANO: I can get the full IOM
10	report as well. I mean, anybody can. It's nid.edu
11	and just send it out.
12	MEMBER BODEN: One other thing that we
13	have to remember is it may be that particular
14	entities that are frequently denied are actually
15	denied for good reason. So it is an we have
16	to keep in mind.
17	CHAIR MARKOWITZ: And we should ask or
18	re-ask DOL if they have a list of the frequency
19	of denied conditions.
20	I think we've asked that before but I
21	don't recall the specifics. But we should at least
22	try or try again if they have information on that.

So, is there anything -- I think we've 1 pretty much discussed most of the things that are 2 3 relevant and even other things. No? Talk is good. Are there any other things relating to 4 presumptions that we need to discuss today? 5 Otherwise we should adjourn. 6 7 Okay. So I'm going to -- let's see, I think Tori is going to send me some suggested 8 I'm going to modify some of the things 9 language. based on comments on the call. 10 Then John Dement's 11 written comment. 12 I'll draft a rationale to go along with 13 this and then circulate this before our fall meeting. 14 I don't think that we have enough 15 business to call for another presumptions working 16 group meeting prior to our fall meeting. 17 Does 18 anybody think otherwise? 19 MEMBER SILVER: Is following up with 20 DOL to see how they're receiving our 21 recommendations something for the working group 22 or something for the full board?

1	CHAIR MARKOWITZ: That's for the full
2	board. Doug gave us a brief report on Monday that
3	things are either within the program being worked
4	on or in the Secretary's office. And that's all
5	we know at this point.
6	But we'll continue to monitor it. And
7	continue to send in new recommendations.
8	MEMBER BODEN: Okay, well Steven, your
9	fear of not having to end well before our designated
10	time has been allayed.
11	CHAIR MARKOWITZ: Okay, that's good.
12	Okay, thank you and we'll continue to communicate
13	around this particular presumption medical section
14	for asbestos related disease.
15	And then we're going to set the schedule
16	for the full meeting in October or November so
17	you'll hear from Carrie. Thank you.
18	(Whereupon, the above-entitled matter
19	went off the record at 3:00 p.m.)
20	
21	
22	